Australia's Immutep rises on positive results from cancer trial
12/07/2024 04:02
** Shares of Immutep IMM.AX rise as much as 27.1% to
A$0.375, their highest since June 27
** Stock posts its biggest intraday pct gain since May 18,
2023
** Biotech firm says got positive results from Cohort B of
the TACTI-003 Phase IIb trial evaluating eftilagimod alfa (efti)
in combination with Merck & Co's MRK.N anti-PD-1 therapy
KEYTRUDA
** The trial is for treatment of head and neck squamous cell
carcinoma, a type of skin cancer
** About 13 mln shares change hands, compared with the
30-day average volume of 6.6 mln
** Stock has fallen nearly 14% this year, as of last close
(Reporting by Sneha Kumar in Bengaluru)
((Sneha.Kumar@thomsonreuters.com;))